Agenda: Day 2

All session times are in Eastern Time (ET)

There are no agenda items with this track

8:00 am

8:00 am

Registration & Breakfast

  • Start your day off right and make connections with market access leaders
  • Interact with your peers, discuss best practices and share innovative strategies
  • Gather essential content and get exclusive offers at sponsor booths

9:00 am

9:00 am

Welcome From Your Chair

Gain insight into today’s sessions so you can get the most out of your experience and maximize your value.

9:10 am

9:10 am

INSIDER FIRESIDE CHAT

Is a two-tiered system the answer to help closing the gap?

What can we glean from a frank discussion among a Provincial Government representative, a manufacturer and a patient advocate? Everyone knows governments are stretched to provide adequate outcomes for those uninsured; is it time for those who can afford it to pay their way and let public payors help those who can’t help themselves?

10:00 am

10:00 am

FIRESIDE CHAT: THE INCREASED OPPORTUNITY FOR PUBLIC / PRIVATE PARTNERSHIPS TO FIX THE SYSTEM

Using Cardiovascular Disease As An Important Example

The healthcare system in Canada has been under tremendous strain for years. The ongoing crisis has been amplified by the pandemic, which caused severe global disruption in the delivery of health care for non-communicable diseases, BUT early detection and diagnosis are critical to keeping people out of hospitals and reducing the need for procedures and surgeries.

Now is the time to take a closer look at how the public and private sectors can band together to drive solutions to crucial healthcare problems, alleviate pressure throughout the system, and drive positive and lasting change.

The issue of cardiovascular disease (CVD) is particularly pressing as it is the second leading cause of death in Canada after cancer and now providers are facing an unprecedented backlog in the need for follow-up care to prevent future heart attacks and strokes among people at elevated risk. Novartis is seeking to address care inequities, barriers to access, and challenges and opportunities, by investing and institutionalizing best-in-class provincial teams to drive partnerships at the local healthcare system level.

10:45 am

10:45 am

Morning Break

  • Engage with conference speakers and fellow attendees
  • Secure new business contacts and discuss crucial developments in market access
  • Exchange innovations and ideas

11:15 am

11:15 am

INDUSTRY EXPERT: REAL-WORLD EVIDENCE

The Importance of Real-World Evidence (RWE) in your Rare Disease Commercialization Strategy

The session will explore how to leverage patient support programs (PSP) throughout a Rare Disease product life cycle. Alison will identify the challenges and opportunities associated with utilizing the RWE collected from the PSP to enable decision-making and market access/commercialization strategies of rare disease therapies. The presentation will focus on the following:

  • Considerations throughout the commercialization journey to incorporate RWE into the PSP launch plan
  • Insights into how a PSP has used RWE in their market access strategy to overcome reimbursement challenges
  • How PSPs should engage with their patients to conduct RWE, with a focus on consent and privacy
  • Uncover complementary sources of data that can be leveraged from outside of the program (EMR, Claims data)

12:00 pm

12:00 pm

PRICING OUTLOOK 2022-2023

IS PMPRB RELEVANT, OR NOT?

The PMPRB considers itself to be in a holding pattern due to the delays in the rollout of the new regime. As such, the two stated priorities for the coming year are the same as they were in the 2021-22 Departmental Plan: (1) to implement the new pricing framework and begin evaluating its impact; and (2) to support the federal government’s high-level priorities for the future of pharmaceutical management in Canada.

12:30 pm

12:30 pm

Networking Lunch

  • Expand your network and make connections that last beyond the event
  • Visit the exhibitor hall and pose your toughest questions to leading consultants
  • Enjoy great food and service while engaging with your pharma colleagues

1:30 pm

1:30 pm

INTERNATIONAL REFERENCE PRICING (IRP) A YEAR LATER:

AN OVERVIEW AND OUTLOOK FOR IRP IN NORTH AMERICA

IRP is a frequently tossed-around term used in reference to controlling rising drug prices in both Canada and the US. Leverage an in-depth understanding of the history and future consequences for your brands/products. Gain critical insights including:

  • Incorporating IRP, the absence of price transparency and role of confidential agreements & patient access schemes
  • Informing yourself via a case study how the new basket of 11 reference countries is intended to lower Canadian drug prices to OECD median
  • Evaluating the proposed US IRP regulatory proposals and their potential for implementation in current political environment

Assess the impact of IRP on your upcoming launch sequencing & patient access

3:00 pm

3:00 pm

Summary and Closing Comments from your Host

Review the key solutions and takeaways from today’s sessions. Source a summary of action points to implement in your work.

3:15 pm

3:15 pm

Conference Adjourns

Get the latest news

*Privacy Policy